What is William Blair’s Estimate for KLRS FY2025 Earnings?

Kalaris Therapeutics Inc. (NASDAQ:KLRS) – Research analysts at William Blair decreased their FY2025 earnings per share estimates for shares of Kalaris Therapeutics in a research note issued on Wednesday, November 12th. William Blair analyst L. Hanbury-Brown now forecasts that the company will earn ($2.86) per share for the year, down from their previous estimate of ($2.66). William Blair also issued estimates for Kalaris Therapeutics’ Q4 2025 earnings at ($0.56) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.60) EPS, Q4 2026 earnings at ($0.58) EPS and FY2026 earnings at ($2.31) EPS.

A number of other analysts have also recently issued reports on KLRS. Piper Sandler set a $3.00 price objective on Kalaris Therapeutics and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. Citizens Jmp initiated coverage on Kalaris Therapeutics in a report on Monday, November 3rd. They set a “market outperform” rating and a $20.00 price target for the company. Wall Street Zen cut shares of Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (e)” rating on shares of Kalaris Therapeutics in a research report on Wednesday, October 8th. Finally, Raymond James Financial assumed coverage on shares of Kalaris Therapeutics in a research note on Tuesday, September 2nd. They set a “strong-buy” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Kalaris Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Kalaris Therapeutics Price Performance

Kalaris Therapeutics stock opened at $5.33 on Friday. The stock’s 50-day simple moving average is $5.06. The company has a market capitalization of $99.67 million, a PE ratio of -1.32 and a beta of 0.42. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $15.63.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.02.

Hedge Funds Weigh In On Kalaris Therapeutics

Hedge funds have recently bought and sold shares of the business. Belpointe Asset Management LLC bought a new stake in Kalaris Therapeutics in the 3rd quarter valued at about $231,000. Fortis Capital Advisors LLC bought a new position in shares of Kalaris Therapeutics during the third quarter worth approximately $231,000. XTX Topco Ltd acquired a new stake in shares of Kalaris Therapeutics in the second quarter valued at approximately $65,000. Finally, Johnson Financial Group Inc. acquired a new stake in shares of Kalaris Therapeutics in the third quarter valued at approximately $58,000. 66.05% of the stock is owned by institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.